Stock Scorecard
Stock Summary for Elevation Oncology Inc (ELEV) - $4.05 as of 5/2/2024 4:03:14 PM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ELEV
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ELEV
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ELEV
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ELEV
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for ELEV
Financial Details for ELEV
Company Overview |
|
---|---|
Ticker | ELEV |
Company Name | Elevation Oncology Inc |
Country | USA |
Description | Elevate, Inc. (Elevate), formerly Highland Business Services, Inc., is a digital service provider with a variety of Internet (IP) protocols and wireless residential services. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 4.05 |
Last Day Price Updated | 5/2/2024 4:03:14 PM EST |
Last Day Volume | 2,660,175 |
Average Daily Volume | 919,996 |
52-Week High | 5.89 |
52-Week Low | 0.36 |
Last Price to 52 Week Low | 1,025.00% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 71.86 |
Sector PE | 54.22 |
5-Year Average PE | -0.37 |
Free Cash Flow Ratio | 2.37 |
Industry Free Cash Flow Ratio | 20.16 |
Sector Free Cash Flow Ratio | 32.33 |
Current Ratio Most Recent Quarter | 21.22 |
Total Cash Per Share | 1.71 |
Book Value Per Share Most Recent Quarter | 1.29 |
Price to Book Ratio | 3.42 |
Industry Price to Book Ratio | 7.49 |
Sector Price to Book Ratio | 22.23 |
Price to Sales Ratio Twelve Trailing Months | 0.00 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.30 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.15 |
Share Statistics |
|
Total Shares Outstanding | 48,651,100 |
Market Capitalization | 197,036,955 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 51.93% |
Reported EPS 12 Trailing Months | -1.34 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -1.53 |
Net Income Twelve Trailing Months | -45,704,000 |
Net Income Past Year | -45,704,000 |
Net Income Prior Year | -95,080,000 |
Quarterly Revenue Growth YOY | 0.00% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 83,107,000 |
Total Cash Past Year | 83,107,000 |
Total Cash Prior Year | 90,280,000 |
Net Cash Position Most Recent Quarter | 52,970,000 |
Net Cash Position Past Year | 52,970,000 |
Long Term Debt Past Year | 30,137,000 |
Long Term Debt Prior Year | 29,435,000 |
Total Debt Most Recent Quarter | 30,137,000 |
Equity to Debt Ratio Past Year | 0.65 |
Equity to Debt Ratio Most Recent Quarter | 0.65 |
Total Stockholder Equity Past Year | 54,809,000 |
Total Stockholder Equity Prior Year | 49,032,000 |
Total Stockholder Equity Most Recent Quarter | 54,809,000 |
Options |
|
Put/Call Ratio | 785.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.17 |
MACD Signal | -0.04 |
20-Day Bollinger Lower Band | 0.49 |
20-Day Bollinger Middle Band | 3.29 |
20-Day Bollinger Upper Band | 6.10 |
Beta | 1.36 |
RSI | 38.03 |
50-Day SMA | 1.99 |
200-Day SMA | 0.00 |
System |
|
Modified | 5/1/2024 11:20:28 PM EST |